ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - IDCW Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 09-07-2018
AUM:
₹ 6,458.59 Cr
Expense Ratio
1.86%
Benchmark
BSE Healthcare TRI
ISIN
INF109KC1GG4
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Dharmesh Kakkad
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - IDCW Option | 1.28 | 26.67 | 16.74 |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
23.22
Last change
-0.06 (-0.2584%)
Fund Size (AUM)
₹ 6,458.59 Cr
Performance
19.81% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Fund Manager
Dharmesh Kakkad
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 12.83 |
| Dr. Reddys Laboratories Ltd | 9.81 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 8.0 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.48 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 6.04 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.7 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 5.04 |
| ALKEM LABORATORIES LIMITED EQ | 3.78 |
| SYNGENE INTERNATIONAL LIMITED EQ | 2.97 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 2.68 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 92.49 |
| Financial Services | 2.71 |
| Consumer Services | 1.34 |
| Chemicals | 1.17 |